Vildagliptin: experience and prospects


Authors: Alena Šmahelová
Authors‘ workplace: III. interní gerontometabolická klinika LF UK v Hradci Králové a FN Hradec Králové
Published in: Forum Diab 2018; 7(1): 0
Category:

Overview

Vildagliptin is one of the modern antidiabetic drugs from the incretin group. It is a dipeptidyl peptidase-4 (DPP-4i) inhibitor, whose effectiveness and safety (including cardiovascular) have been proven in a number of preclinical, randomized clinical and large-scale international observation studies in clinical practice. These effects have also been verified in elderly patients with type 2 diabetes and in patients with type 2 diabetes a renal impairment. Currently its effect on patients in early stages of diabetes is being tested, which is essential for further course of dia­betes with the development of late complications.

Key words:
actual clinical practice, clinical studies, complications of diabetes, effectiveness, safety, vildagliptin

Received:
17. 2. 2018

Accepted:
5. 3. 2018


Sources

1. Marfella R, Barbieri M, Grella R et al. Effects of vildagliptin twice daily vs. sitagliptin once daily on 24-hour acute glucose fluctuations. J Diabetes Complications 2010; 24(2): 79–83. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jdiacomp.2009.01.004>.

2. Rizzo MR, Barbieri M, Marfella R et al. Reduction of oxidative stress and inflammation by blunting daily acute glucose fluctuations in patients with type 2 diabetes: role of dipeptidyl peptidase-IV inhibition. Diabetes Care 2012; 35(10): 2076–2082. Dostupné z DOI: <http://dx.doi.org/10.2337/dc12–0199>. Erratum in Diabetes Care 2014; 37(2): 587.

3. Barbieri M, Rizzo MR, Marfella R et al. Decreased carotid atherosclerotic process by control of daily acute glucose fluctuations in diabetic patients treated by DPP-IV inhibitors. Atherosclerosis 2013; 227(2): 349–354. Dostupné z DOI: <http://dx.doi.org/10.1016/j.atherosclerosis.2012.12.018>.

4. Alagiakrishnan K, Sankaralingam S, Ghosh M et al. Antidiabetic drugs and their potential role in treating mild cognitive impairment and Alzheimer‘s disease. Discov Med 2013; 16(90): 277–286.

5. Ma QH, Jiang LF, Mao JL et al. Vildagliptin prevents cognitive deficits and neuronal apoptosis in a rat model of Alzheimer‘s disease. Mol Med Rep 2018; 17(3): 4113–4119. Dostupné z DOI: <http://dx.doi.org/10.3892/mmr.2017.8289>.

6. Blüher M, Schweizer A, Bader G et al. Changes in body weight after 24 weeks of vildagliptin therapy as a function of fasting glucose levels in patients with type 2 diabetes. Vasc Health Risk Manag 2014; 10: 661–664. Dostupné z DOI: <http://dx.doi.org/10.2147/VHRM.S73608>.

7. International Diabetes Federation. Managing Older People with Type 2 Diabetes: Global Guideline. International Diabetes Federation: 2013. ISBN 2–930229–86–1. Dostupné z WWW: .

8. Konrat C, Boutron I, Trinquart L et al. Underrepresentation of elderly people in randomised controlled trials. The example of trials of 4 widely prescribed drugs. PLoS One 2012;7:e33559. Dostupné z DOI: <http://dx.doi.org/10.1371/journal.pone.0033559>.

9. Strain WD, Agarwal AS, Paldanius PM. Individualizing treatment targets for elderly patients with type 2 diabetes: factors influencing clinical decision making in the 24-week, randomized INTERVAL study. Aging (Albany NY) 2017; 9(3): 769–777. Dostupné z DOI: <http://dx.doi.org/10.18632/aging.101188>.

10. Parving HH, Lewis JB, Ravid M et al. Prevalence and risk factors for microalbuminuria in a referred cohort of type II diabetic patients: A global perspective. Kidney Int 2006, 69(11): 2057–2063. Dostupné z DOI: <http://dx.doi.org/10.1038/sj.ki.5000377>.

11. He YL, Kulmatycki K, Zhang Y et al. Pharmacokinetics of vildagliptin in patients with varying degrees of renal impairment. Int J Clin Pharmacol Ther 2013; 51(9):693–703. Dostupné z DOI: <http://dx.doi.org/10.5414/CP201885>.

12. Kothny W, Shao Q, Groop PH et al. One-year safety, tolerability and efficacy of vildagliptin in patients with type 2 diabetes and moderate or severe renal impairment. Diabetes Obes Metab 2012; 14(11): 1032–1039. Dostupné z DOI: <http://dx.doi.org/10.1111/j.1463–1326.2012.01634.x>.

13. Groop PH, Cooper ME, Perkovic V et al. Linagliptin lowers albuminuria on top of recommended standard treatment in patients with type 2 diabetes and renal dysfunction. Diabetes Care 2013; 36(11): 3460–3468. Dostupné z DOI: <http://dx.doi.org/10.2337/dc13–0323>.

14. Scirica BM, Bhatt DL, Braunwald E et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013; 369(14): 1317–1326. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1307684>.

15. Monami M, Ahren B, Dicembrini I et al. Dipeptidylpeptidase-4 inhibitors and cardiovascular risk: a metaanalysis of randomized clinical trials. Diabetes Obes Metab 2013; 15(2): 112–120. Dostupné z DOI: <http://dx.doi.org/10.1111/dom.12000>.

16. Marso SP, Daniels GH, Brown-Frandsen K et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016; 375(4): 311–322. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1603827>.

17. Mathieu C, Barnett AH, Brath H et al., Effectiveness andtolerability of second-line therapy with vildagliptin vs. other oral agents in type 2 diabetes: a real-life worldwide observational study (EDGE). Int J Clin Pract 2013;67(10): 947–956. Dostupné z DOI: <http://dx.doi.org/10.1111/ijcp.12252>.

18. VERIFY: A study to compare combination regimen with vildagliptin & metformin versus metformin in treatment-naďve patients with type 2 diabetes mellitus. ClinicalTrials.gov Identifier: NCT01528254. Dostupné z WWW: <https://clinicaltrials.gov/ct2/show/NCT01528254>.

19. [World Health Organization (WHO)]. Prevention of Blindness from Diabetes Mellitus 2017. WHO: 2017. ISBN 9789241547123. Dostupné z WWW: <http://www.who.int/blindness/en/>.

20. [World Health Organization (WHO)]. Diabetes Fact Sheet. 2018. Dostupné z WWW: <http://www.who.int/mediacentre>.

21. Liebl A, Mata M, Eschwège E. [ODE-2 Advisory Board]. Evaluation of risk factors for development of complications in Type II diabetes in Europe. Diabetologia 2002; 45(7 Suppl 1): S23–28.

22. de Pablos-Velasco P; Bradley P, Eschwège E et al. The PANORAMA pan-European survey: glycaemic control and treatment patterns in patients with type 2 diabetes. Diabetologia 2010; 53(Suppl 1): Abstract 1012.

23. Ali MK, Bullard KM, Saaddine JB et al. Achievement of goals in U.S. diabetes care, 1999–2010. N Engl J Med 2013; 368(17): 1613–1624. Dostupné z DOI: <http://doi: 10.1056/NEJMsa1213829>. Erratum in N Engl J Med. 2013; 369(6): 587.

24. de Pablos-Velasco P, Parhofer KG, Bradley C et al. Current level of glycaemic control and its associated factors in patients with type 2 diabetes across Europe: data from the PANORAMA study. Clin Endocrinol (Oxf) 2014; 80(1): 47–56. Dostupné z DOI: <http://dx.doi.org/10.1111/cen.12119>.

25. Viberti G, Kahn SE, Greene DA et al. A Diabetes Outcome Progression Trial (ADOPT): An international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care 2002; 25(10): 1737–1743.

26. Patel A, MacMahon S, Chalmers J et al. [The ADVANCE Collaborative Group]. Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med 2008; 358(24): 2560–2572. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa0802987>.

27. Williamson DF, Thompson TJ, Thun M et al. Intentional weight loss and mortality among overweight individuals with diabetes. Diabetes Care 2000; 23(10): 1499–1504.

28. Ten Years of Vildagliptin. European Endocrinology 2017; 13(2): 54–72.

Labels
Diabetology Endocrinology Internal medicine
Login
Forgotten password

Don‘t have an account?  Create new account

Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account